IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We recently reported that 16 weeks of sublingual immunotherapy (SLIT) with recombinant (r) Mal d 1, but not rBet v 1, significantly improved birch pollen-related apple allergy. Allergen-specific IgE-blocking IgG antibodies have been associated with clinical efficacy. OBJECTIVE: We compared the quantity, quality, and IgE-blocking bioactivity of SLIT-induced Mal d 1-specific IgG antibodies in both treatment groups. METHODS: Pre- and post-SLIT sera were assessed for rMal d 1-specific IgG antibodies in ELISA and for their ability to inhibit apple allergen-induced upregulation of CD63 on basophils from nontreated individuals with birch pollen-related apple allergy. Post-SLIT sera depleted of IgG1 or IgG4 were compared for their IgE-blocking activity. IgG1 binding to rMal d 1 was competed with rMal d 1 and rBet v 1 in ELISA. RESULTS: SLIT with rMal d 1 and rBet v 1 induced comparable levels of rMal d 1-specific IgG1, IgG2, IgG3, and IgG4 antibodies. Only post-rMal d 1 SLIT sera displayed IgE-blocking activity, which was significantly reduced by depletion of IgG1 and less so by IgG4 depletion. In competition ELISA, IgG1 binding to Mal d 1 in post-rMal d 1 SLIT sera was fully inhibited with rMal d 1 but not with rBet v 1. Correspondingly, Bet v 1 was the more potent competitor for IgG1 binding to Mal d 1 in post-rBet v 1 SLIT sera. CONCLUSION: rMal d 1 SLIT for 16 weeks induced functional, primarily Mal d 1-specific IgE-blocking antibodies, whereas rBet v 1 SLIT induced Bet v 1-specific, Mal d 1-cross-reactive IgG antibodies with limited cross-blocking activity. These results provide a possible explanation for the limited effectiveness of birch pollen immunotherapy in birch pollen-related food allergy and indicate a dominant protective role of functional IgE-blocking IgG1 antibodies in the early phase of allergy treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asero (1998) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1998.00399.x · Cited by 195
How long does the effect of birch pollen injection SIT on apple allergy last?
Asero, R. (2003) · Allergy · doi:10.1034/j.1398-9995.2003.00139.x · Cited by 94
Birch-Apple Syndrome Treated with Birch Pollen Immunotherapy
Mauro, M., Russello, M., Incorvaia, C., Gazzola, G., Frati, F., Moingeon, P., & Passalacqua, G. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000323909 · Cited by 90
Cited by
EAACI Molecular Allergology User's Guide 2.0
Dramburg, S., Hilger, C., Santos, A. F., de las Vecillas, L., Aalberse, R. C., Acevedo, N., Aglas, L., Altmann, F., Arruda, K. L., Asero, R., et al. (2023) · Pediatric Allergy and Immunology · doi:10.1111/pai.13854 · Cited by 298
Update on Pollen-Food Allergy Syndrome
Poncet, P., Sénéchal, H., & Charpin, D. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1774366 · Cited by 105
Molecular Allergology and Its Impact in Specific Allergy Diagnosis and Therapy
Barber, D., Diaz‐Perales, A., Escribese, M. M., Kleine‐Tebbe, J., Matricardi, P. M., Ollert, M., Santos, A. F., & Sastre, J. (2021) · Allergy · doi:10.1111/all.14969 · Cited by 59
Kato, Y., Morikawa, T., & Fujieda, S. (2025) · Allergology International · doi:10.1016/j.alit.2024.08.007 · Cited by 45
Sakamoto, D., Hamada, S., Kobayashi, Y., Shimono, M., Shimamura, A., Kanda, A., Asako, M., & Iwai, H. (2023) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.12.001 · Cited by 11
Metadata
- Authors
- Sánchez Acosta, G., Kinaciyan, T., Kitzmüller, C., Möbs, C., Pfützner, W., & Bohle, B.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 146
- Issue
- 4
- Pages
- 894-900.e2
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3014664073
- Cited by
- 58
- References
- 3
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.